Mood Emot.  2018 Nov;16(3):109-122. 10.0000/me.2018.16.3.109.

Korean Medication Algorithm for Bipolar Disorder 2018 : Children and Adolescents

Affiliations
  • 1Department of Psychiatry, Soonchunhyang University Cheonan Hospital, Soonchunhyang University, Cheonan, Korea.
  • 2Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea. wmbahk@catholic.ac.kr
  • 3Department of Psychiatry, Naju National Hospital, Naju, Korea.
  • 4Department of Psychiatry, Sacred Heart Hospital, Hallym University, Anyang, Korea.
  • 5Department of Psychiatry, School of Medicine, Konkuk University, Chungju, Korea.
  • 6Department of Psychiatry, Seoul Paik Hospital, College of Medicine, Inje University, Seoul, Korea.
  • 7Department of Psychiatry, Haeundae Paik Hospital, College of Medicine, Inje University and Paik Institute for Clinical Research and Department of Health Science and Technology, Graduate School of Inje University, Busan, Korea.
  • 8Department of Psychiatry, Jeju National University Hospital, Jeju, Korea.
  • 9Department of Psychiatry, Keyo Hospital, Keyo Medical Foundation, Uiwang, Korea.
  • 10Department of Psychiatry, Myongji Hospital, Goyang, Korea.
  • 11Department of Psychiatry, College of Medicine, Chung-Ang University, Seoul, Korea. kjoonmin@gmail.com

Abstract


OBJECTIVES
The objective of this study was to revise the Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) 2014: Children and Adolescents.
METHODS
We performed the survey, using a questionnaire comprising 22 questions according to each situation, in children and adolescents with bipolar disorder.
RESULTS
First-line pharmacotherapeutic strategies for manic episode in children with bipolar disorder were a combination of mood stabilizer (MS) and an atypical antipsychotics (AAP), monotherapy with an AAP, risperidone, and aripiprazole. Aripiprazole was selected as first-line medication for depressive episode in children with bipolar disorder, and aripiprazole, and risperidone were selected as first-line at high-risk children. First-line pharmacotherapeutic strategies for manic episode in adolescents were a combination of MS and an AAP, monotherapy with an AAP valproate, lithium, risperidone (Treatment of Choice, TOC), aripiprazole, and quetiapine. First-line pharmacotherapeutic strategies for depressive episode in adolescents, were a combination of an atypical antipsychotics and lamotrigine, valproate, aripiprazole (TOC), risperidone, and quetiapine. For depressive episodes in adolescents at high risk for bipolar disorder, valproate, aripiprazole (TOC), and risperidone were selected as first-line medication.
CONCLUSION
We expect that the present KMAP-BP 2018-children and adolescents, is useful for clinicians to treat children and adolescents with bipolar disorder.

Keyword

Bipolar disorder; Children and adolescents; Pharmacotherapy; KMAP-BP 2018

MeSH Terms

Adolescent*
Antipsychotic Agents
Aripiprazole
Bipolar Disorder*
Child*
Drug Therapy
Humans
Lithium
Quetiapine Fumarate
Risperidone
Valproic Acid
Antipsychotic Agents
Aripiprazole
Lithium
Quetiapine Fumarate
Risperidone
Valproic Acid
Full Text Links
  • ME
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr